{"id":389,"date":"2021-10-15T15:39:29","date_gmt":"2021-10-15T19:39:29","guid":{"rendered":"http:\/\/herpescureadvocacy.com\/2021\/10\/15\/pritelivir-clinical-trials-recruiting\/"},"modified":"2026-05-05T21:23:29","modified_gmt":"2026-05-06T01:23:29","slug":"pritelivir-clinical-trials-recruiting","status":"publish","type":"post","link":"https:\/\/herpescureadvocacy.com\/2021\/10\/15\/pritelivir-clinical-trials-recruiting\/","title":{"rendered":"Pritelivir: Clinical Trial Recruiting for resistant Herpes Simplex Virus Infection in immune compromised Patients"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">AiCuris AG, a German biotech company, is currently recruiting for their clinical trial on Pritelivir. Pritelivir is a highly anticipated new treatment for resistant Herpes Simplex Virus infections that cannot be managed with the available anti-virals. It is currently being tested for immune compromised patients only and, if proven safe and effective, could become a new treatment option for this population.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link <a href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03073967?term=Pritelivir&amp;draw=2&amp;rank=2#contacts\">here<\/a> with more details on criteria and how to apply.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Patients they are recruiting for:<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Group C: For patients that are immune compromised and Acyclovir resistant<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Group D: For patients that are immune compromised and present (or develop through the course of trials) foscarnet resistance\/intolerance<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Group E: For patients that are immune compromised but are responsive to Acyclovir<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">There are additional inclusion and exclusion criteria so please check the trial page on ClinicalTrials.gov on the link above.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Not all centers are already open and recruiting so if the one in your area is not recruiting yet you may want to contact them to be added to a waitlist.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Testing locations:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Los Angeles, California<\/li>\n\n\n\n<li>New Haven, Connecticut<\/li>\n\n\n\n<li>DeLand, Florida<\/li>\n\n\n\n<li>For Pierce, Florida<\/li>\n\n\n\n<li>Atlanta, Georgia<\/li>\n\n\n\n<li>Chicago, Illinois<\/li>\n\n\n\n<li>Baton Rouge, Louisiana<\/li>\n\n\n\n<li>Baltimore, Maryland<\/li>\n\n\n\n<li>Boston, Massachusetts<\/li>\n\n\n\n<li>Detroit, Michigan<\/li>\n\n\n\n<li>Pittsburgh, Pennsylvania<\/li>\n\n\n\n<li>Houston, Texas<\/li>\n\n\n\n<li>Seattle, Washington<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-css-opacity\"\/>\n\n\n\n<h5 id=\"get-in-touch\" class=\"wp-block-heading\">Get in touch<\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Stay informed of the latest research news and advocacy updates. <a href=\"https:\/\/herpescureadvocacy.com\/#newsletter\">Sign up<\/a> for Herpes Cure Advocacy news!<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Questions? Email us: <a href=\"mailto:info@herpescureadvocacy.com\">info@herpescureadvocacy.com<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AiCuris AG, a German biotech company, is currently recruiting for their clinical trial on Pritelivir. Pritelivir is a highly anticipated new treatment for resistant Herpes Simplex Virus infections that cannot<a class=\"more-link\" href=\"https:\/\/herpescureadvocacy.com\/2021\/10\/15\/pritelivir-clinical-trials-recruiting\/\">Continue reading <span class=\"screen-reader-text\">&#8220;Pritelivir: Clinical Trial Recruiting for resistant Herpes Simplex Virus Infection in immune compromised Patients&#8221;<\/span><\/a><\/p>\n","protected":false},"author":205069572,"featured_media":369,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"{title}\n\n{excerpt}\n\n{url}","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"_wpas_customize_per_network":false,"jetpack_post_was_ever_published":false},"categories":[5967],"tags":[719338643,2871574,5890257,5004,103,88731,84527,719338644,52877],"class_list":["post-389","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-advocacy","tag-advocacy","tag-herpes-simplex-virus","tag-hsv-2","tag-mental-health","tag-news","tag-patients","tag-prevention","tag-treatment","tag-vaccine","entry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pritelivir: Clinical Trial Recruiting for resistant Herpes Simplex Virus Infection in immune compromised Patients - Herpes Cure Advocacy<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/herpescureadvocacy.com\/2021\/10\/15\/pritelivir-clinical-trials-recruiting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pritelivir: Clinical Trial Recruiting for resistant Herpes Simplex Virus Infection in immune compromised Patients - Herpes Cure Advocacy\" \/>\n<meta property=\"og:description\" content=\"AiCuris AG, a German biotech company, is currently recruiting for their clinical trial on Pritelivir. Pritelivir is a highly anticipated new treatment for resistant Herpes Simplex Virus infections that cannotContinue reading &quot;Pritelivir: Clinical Trial Recruiting for resistant Herpes Simplex Virus Infection in immune compromised Patients&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/herpescureadvocacy.com\/2021\/10\/15\/pritelivir-clinical-trials-recruiting\/\" \/>\n<meta property=\"og:site_name\" content=\"Herpes Cure Advocacy\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=100087212780212\" \/>\n<meta property=\"article:published_time\" content=\"2021-10-15T19:39:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-06T01:23:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2021\/10\/img_1044.jpg?fit=1000%2C638&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"638\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Patient Advocate\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@herpesadvocate\" \/>\n<meta name=\"twitter:site\" content=\"@herpesadvocate\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Patient Advocate\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2021\\\/10\\\/15\\\/pritelivir-clinical-trials-recruiting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2021\\\/10\\\/15\\\/pritelivir-clinical-trials-recruiting\\\/\"},\"author\":{\"name\":\"Patient Advocate\",\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/#\\\/schema\\\/person\\\/5a8a408f85fcdaa526d3173c93216d14\"},\"headline\":\"Pritelivir: Clinical Trial Recruiting for resistant Herpes Simplex Virus Infection in immune compromised Patients\",\"datePublished\":\"2021-10-15T19:39:29+00:00\",\"dateModified\":\"2026-05-06T01:23:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2021\\\/10\\\/15\\\/pritelivir-clinical-trials-recruiting\\\/\"},\"wordCount\":244,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2021\\\/10\\\/15\\\/pritelivir-clinical-trials-recruiting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/herpescureadvocacy.com\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/img_1044.jpg?fit=1000%2C638&ssl=1\",\"keywords\":[\"Advocacy\",\"Herpes Simplex Virus\",\"HSV-2\",\"Mental Health\",\"News\",\"Patients\",\"Prevention\",\"Treatment\",\"Vaccine\"],\"articleSection\":[\"Advocacy\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/herpescureadvocacy.com\\\/2021\\\/10\\\/15\\\/pritelivir-clinical-trials-recruiting\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2021\\\/10\\\/15\\\/pritelivir-clinical-trials-recruiting\\\/\",\"url\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2021\\\/10\\\/15\\\/pritelivir-clinical-trials-recruiting\\\/\",\"name\":\"Pritelivir: Clinical Trial Recruiting for resistant Herpes Simplex Virus Infection in immune compromised Patients - Herpes Cure Advocacy\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2021\\\/10\\\/15\\\/pritelivir-clinical-trials-recruiting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2021\\\/10\\\/15\\\/pritelivir-clinical-trials-recruiting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/herpescureadvocacy.com\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/img_1044.jpg?fit=1000%2C638&ssl=1\",\"datePublished\":\"2021-10-15T19:39:29+00:00\",\"dateModified\":\"2026-05-06T01:23:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2021\\\/10\\\/15\\\/pritelivir-clinical-trials-recruiting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/herpescureadvocacy.com\\\/2021\\\/10\\\/15\\\/pritelivir-clinical-trials-recruiting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2021\\\/10\\\/15\\\/pritelivir-clinical-trials-recruiting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/herpescureadvocacy.com\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/img_1044.jpg?fit=1000%2C638&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/herpescureadvocacy.com\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/img_1044.jpg?fit=1000%2C638&ssl=1\",\"width\":1000,\"height\":638,\"caption\":\"Female Scientist Working in The Lab, Using Computer Screen\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2021\\\/10\\\/15\\\/pritelivir-clinical-trials-recruiting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/herpescureadvocacy.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pritelivir: Clinical Trial Recruiting for resistant Herpes Simplex Virus Infection in immune compromised Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/#website\",\"url\":\"https:\\\/\\\/herpescureadvocacy.com\\\/\",\"name\":\"Herpes Cure Advocacy\",\"description\":\"Advocating for a cure for Herpes Simplex Virus.\",\"publisher\":{\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/herpescureadvocacy.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/#organization\",\"name\":\"Herpes Cure Advocacy\",\"url\":\"https:\\\/\\\/herpescureadvocacy.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/herpescureadvocacy.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/HCA-main-logo.png?fit=450%2C110&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/herpescureadvocacy.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/HCA-main-logo.png?fit=450%2C110&ssl=1\",\"width\":450,\"height\":110,\"caption\":\"Herpes Cure Advocacy\"},\"image\":{\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=100087212780212\",\"https:\\\/\\\/x.com\\\/herpesadvocate\",\"https:\\\/\\\/www.instagram.com\\\/herpesadvocate\",\"https:\\\/\\\/www.reddit.com\\\/r\\\/HerpesCureAdvocates\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/herpes-cure-advocacy\\\/\",\"https:\\\/\\\/www.tiktok.com\\\/@herpes.advocate?lang=en\",\"https:\\\/\\\/themighty.com\\\/groups\\\/herpescureadvocacy\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/#\\\/schema\\\/person\\\/5a8a408f85fcdaa526d3173c93216d14\",\"name\":\"Patient Advocate\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/05ebcf007475af5bc907f5c9cdd152a398b8131b81e5609a9fdde2882fc76cfd?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/05ebcf007475af5bc907f5c9cdd152a398b8131b81e5609a9fdde2882fc76cfd?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/05ebcf007475af5bc907f5c9cdd152a398b8131b81e5609a9fdde2882fc76cfd?s=96&d=identicon&r=g\",\"caption\":\"Patient Advocate\"},\"sameAs\":[\"http:\\\/\\\/herpescureadvocacy.com\"],\"url\":\"https:\\\/\\\/herpescureadvocacy.com\\\/author\\\/herpescureadvocacy\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pritelivir: Clinical Trial Recruiting for resistant Herpes Simplex Virus Infection in immune compromised Patients - Herpes Cure Advocacy","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/herpescureadvocacy.com\/2021\/10\/15\/pritelivir-clinical-trials-recruiting\/","og_locale":"en_US","og_type":"article","og_title":"Pritelivir: Clinical Trial Recruiting for resistant Herpes Simplex Virus Infection in immune compromised Patients - Herpes Cure Advocacy","og_description":"AiCuris AG, a German biotech company, is currently recruiting for their clinical trial on Pritelivir. Pritelivir is a highly anticipated new treatment for resistant Herpes Simplex Virus infections that cannotContinue reading \"Pritelivir: Clinical Trial Recruiting for resistant Herpes Simplex Virus Infection in immune compromised Patients\"","og_url":"https:\/\/herpescureadvocacy.com\/2021\/10\/15\/pritelivir-clinical-trials-recruiting\/","og_site_name":"Herpes Cure Advocacy","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=100087212780212","article_published_time":"2021-10-15T19:39:29+00:00","article_modified_time":"2026-05-06T01:23:29+00:00","og_image":[{"width":1000,"height":638,"url":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2021\/10\/img_1044.jpg?fit=1000%2C638&ssl=1","type":"image\/jpeg"}],"author":"Patient Advocate","twitter_card":"summary_large_image","twitter_creator":"@herpesadvocate","twitter_site":"@herpesadvocate","twitter_misc":{"Written by":"Patient Advocate","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/herpescureadvocacy.com\/2021\/10\/15\/pritelivir-clinical-trials-recruiting\/#article","isPartOf":{"@id":"https:\/\/herpescureadvocacy.com\/2021\/10\/15\/pritelivir-clinical-trials-recruiting\/"},"author":{"name":"Patient Advocate","@id":"https:\/\/herpescureadvocacy.com\/#\/schema\/person\/5a8a408f85fcdaa526d3173c93216d14"},"headline":"Pritelivir: Clinical Trial Recruiting for resistant Herpes Simplex Virus Infection in immune compromised Patients","datePublished":"2021-10-15T19:39:29+00:00","dateModified":"2026-05-06T01:23:29+00:00","mainEntityOfPage":{"@id":"https:\/\/herpescureadvocacy.com\/2021\/10\/15\/pritelivir-clinical-trials-recruiting\/"},"wordCount":244,"commentCount":0,"publisher":{"@id":"https:\/\/herpescureadvocacy.com\/#organization"},"image":{"@id":"https:\/\/herpescureadvocacy.com\/2021\/10\/15\/pritelivir-clinical-trials-recruiting\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2021\/10\/img_1044.jpg?fit=1000%2C638&ssl=1","keywords":["Advocacy","Herpes Simplex Virus","HSV-2","Mental Health","News","Patients","Prevention","Treatment","Vaccine"],"articleSection":["Advocacy"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/herpescureadvocacy.com\/2021\/10\/15\/pritelivir-clinical-trials-recruiting\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/herpescureadvocacy.com\/2021\/10\/15\/pritelivir-clinical-trials-recruiting\/","url":"https:\/\/herpescureadvocacy.com\/2021\/10\/15\/pritelivir-clinical-trials-recruiting\/","name":"Pritelivir: Clinical Trial Recruiting for resistant Herpes Simplex Virus Infection in immune compromised Patients - Herpes Cure Advocacy","isPartOf":{"@id":"https:\/\/herpescureadvocacy.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/herpescureadvocacy.com\/2021\/10\/15\/pritelivir-clinical-trials-recruiting\/#primaryimage"},"image":{"@id":"https:\/\/herpescureadvocacy.com\/2021\/10\/15\/pritelivir-clinical-trials-recruiting\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2021\/10\/img_1044.jpg?fit=1000%2C638&ssl=1","datePublished":"2021-10-15T19:39:29+00:00","dateModified":"2026-05-06T01:23:29+00:00","breadcrumb":{"@id":"https:\/\/herpescureadvocacy.com\/2021\/10\/15\/pritelivir-clinical-trials-recruiting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/herpescureadvocacy.com\/2021\/10\/15\/pritelivir-clinical-trials-recruiting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/herpescureadvocacy.com\/2021\/10\/15\/pritelivir-clinical-trials-recruiting\/#primaryimage","url":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2021\/10\/img_1044.jpg?fit=1000%2C638&ssl=1","contentUrl":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2021\/10\/img_1044.jpg?fit=1000%2C638&ssl=1","width":1000,"height":638,"caption":"Female Scientist Working in The Lab, Using Computer Screen"},{"@type":"BreadcrumbList","@id":"https:\/\/herpescureadvocacy.com\/2021\/10\/15\/pritelivir-clinical-trials-recruiting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/herpescureadvocacy.com\/"},{"@type":"ListItem","position":2,"name":"Pritelivir: Clinical Trial Recruiting for resistant Herpes Simplex Virus Infection in immune compromised Patients"}]},{"@type":"WebSite","@id":"https:\/\/herpescureadvocacy.com\/#website","url":"https:\/\/herpescureadvocacy.com\/","name":"Herpes Cure Advocacy","description":"Advocating for a cure for Herpes Simplex Virus.","publisher":{"@id":"https:\/\/herpescureadvocacy.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/herpescureadvocacy.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/herpescureadvocacy.com\/#organization","name":"Herpes Cure Advocacy","url":"https:\/\/herpescureadvocacy.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/herpescureadvocacy.com\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2026\/03\/HCA-main-logo.png?fit=450%2C110&ssl=1","contentUrl":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2026\/03\/HCA-main-logo.png?fit=450%2C110&ssl=1","width":450,"height":110,"caption":"Herpes Cure Advocacy"},"image":{"@id":"https:\/\/herpescureadvocacy.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=100087212780212","https:\/\/x.com\/herpesadvocate","https:\/\/www.instagram.com\/herpesadvocate","https:\/\/www.reddit.com\/r\/HerpesCureAdvocates\/","https:\/\/www.linkedin.com\/company\/herpes-cure-advocacy\/","https:\/\/www.tiktok.com\/@herpes.advocate?lang=en","https:\/\/themighty.com\/groups\/herpescureadvocacy\/"]},{"@type":"Person","@id":"https:\/\/herpescureadvocacy.com\/#\/schema\/person\/5a8a408f85fcdaa526d3173c93216d14","name":"Patient Advocate","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/05ebcf007475af5bc907f5c9cdd152a398b8131b81e5609a9fdde2882fc76cfd?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/05ebcf007475af5bc907f5c9cdd152a398b8131b81e5609a9fdde2882fc76cfd?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/05ebcf007475af5bc907f5c9cdd152a398b8131b81e5609a9fdde2882fc76cfd?s=96&d=identicon&r=g","caption":"Patient Advocate"},"sameAs":["http:\/\/herpescureadvocacy.com"],"url":"https:\/\/herpescureadvocacy.com\/author\/herpescureadvocacy\/"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2021\/10\/img_1044.jpg?fit=1000%2C638&ssl=1","jetpack_likes_enabled":true,"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pcZX4e-6h","jetpack-related-posts":[{"id":2077,"url":"https:\/\/herpescureadvocacy.com\/2023\/03\/29\/promising-progress-in-clinical-trials-for-pritelivir\/","url_meta":{"origin":389,"position":0},"title":"Promising Progress in clinical trials for Pritelivir","author":"Patient Advocate","date":"March 29, 2023","format":false,"excerpt":"Positive news abounds for the Aicuris team, and patients living with HSV, with the release of new results from their Phase three clinical trials for Pritelivir and initiation of a new clinical trial studying the use of Pritelivir in healthy patients. Pritelivir was found to be safe and well tolerated\u2026","rel":"","context":"With 1 comment","block_context":{"text":"With 1 comment","link":"https:\/\/herpescureadvocacy.com\/2023\/03\/29\/promising-progress-in-clinical-trials-for-pritelivir\/#comments"},"img":{"alt_text":"five oblong medication pills","src":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/03\/pexels-photo-593451.jpeg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/03\/pexels-photo-593451.jpeg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/03\/pexels-photo-593451.jpeg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/03\/pexels-photo-593451.jpeg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/03\/pexels-photo-593451.jpeg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/03\/pexels-photo-593451.jpeg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":1469,"url":"https:\/\/herpescureadvocacy.com\/2022\/12\/01\/meet-the-experts\/","url_meta":{"origin":389,"position":1},"title":"Meet the Experts","author":"Patient Advocate","date":"December 1, 2022","format":false,"excerpt":"A series of talks with experts in herpes simplex virus research, commercial partners in vaccine or treatment development, sexual health, and more. Learn more about clinical trials, the latest science, advances in technology, and the role of patient advocacy. UPenn\/BioNTech Clinical Trials: Latest updates and Q&A with Dr Harvey Friedman\u2026","rel":"","context":"With 1 comment","block_context":{"text":"With 1 comment","link":"https:\/\/herpescureadvocacy.com\/2022\/12\/01\/meet-the-experts\/#comments"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2021\/10\/img_1044.jpg?fit=1000%2C638&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2021\/10\/img_1044.jpg?fit=1000%2C638&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2021\/10\/img_1044.jpg?fit=1000%2C638&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2021\/10\/img_1044.jpg?fit=1000%2C638&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":1239,"url":"https:\/\/herpescureadvocacy.com\/2022\/05\/19\/new-clinical-trial-for-herpes-simplex-virus\/","url_meta":{"origin":389,"position":2},"title":"New Clinical Trial for Herpes Simplex Virus","author":"Patient Advocate","date":"May 19, 2022","format":false,"excerpt":"GlaxoSmithKline Pipeline UpdateGSK has officially updated its clinical research pipeline to include a vaccine for HSV-2! Their therapeutic vaccine for HSV-2 isn't mRNA (or what they called SAM technology) but an adjuvanted therapeutic vaccine. The trial (currently recruiting) is a Phase 1\/2 combined trial that ends in 2024. GSK will\u2026","rel":"","context":"With 2 comments","block_context":{"text":"With 2 comments","link":"https:\/\/herpescureadvocacy.com\/2022\/05\/19\/new-clinical-trial-for-herpes-simplex-virus\/#comments"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2022\/05\/download.jpg?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]},{"id":169,"url":"https:\/\/herpescureadvocacy.com\/2021\/05\/24\/what-is-the-timeline-for-a-herpes-cure\/","url_meta":{"origin":389,"position":3},"title":"What is the timeline for a Herpes Cure?","author":"Patient Advocate","date":"May 24, 2021","format":false,"excerpt":"The most frequently asked question in our community? What is the timeline for a Herpes Cure? When will there be a herpes cure? There have always been companies working towards better treatments, vaccines, and cures for HSV-1 and HSV-2, and many have failed. But recently two events changed the possible\u2026","rel":"","context":"In \"Advocacy\"","block_context":{"text":"Advocacy","link":"https:\/\/herpescureadvocacy.com\/tag\/advocacy\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2021\/05\/winter-view.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2021\/05\/winter-view.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2021\/05\/winter-view.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2021\/05\/winter-view.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2021\/05\/winter-view.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2021\/05\/winter-view.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":1861,"url":"https:\/\/herpescureadvocacy.com\/2022\/12\/30\/biontech-new-clinical-trial-for-herpes-vaccine-begins\/","url_meta":{"origin":389,"position":4},"title":"BioNTech New Clinical Trial for Herpes Vaccine begins","author":"Patient Advocate","date":"December 30, 2022","format":false,"excerpt":"December 21 2022, BioNTech announced they had dosed the first clinical trial participant. This is the first-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163. Company statement; \u201cWe aim to help address diseases with a high unmet medical need and of global health\u2026","rel":"","context":"With 1 comment","block_context":{"text":"With 1 comment","link":"https:\/\/herpescureadvocacy.com\/2022\/12\/30\/biontech-new-clinical-trial-for-herpes-vaccine-begins\/#comments"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2022\/12\/pexels-photo-6804927.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2022\/12\/pexels-photo-6804927.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2022\/12\/pexels-photo-6804927.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2022\/12\/pexels-photo-6804927.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2022\/12\/pexels-photo-6804927.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2022\/12\/pexels-photo-6804927.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":4168,"url":"https:\/\/herpescureadvocacy.com\/2024\/07\/24\/impressions-from-ihw-2024\/","url_meta":{"origin":389,"position":5},"title":"Impressions from IHW 2024","author":"Patient Advocate","date":"July 24, 2024","format":false,"excerpt":"This year\u2019s conference highlighted several innovative studies focusing on interventions and antivirals targeting Herpes Simplex Viruses (HSV). Below, we summarize the key findings and their potential impacts on the treatment of HSV infections. Gene Editing Therapy for HSV One of the most promising developments presented was a gene editing therapy\u2026","rel":"","context":"With 1 comment","block_context":{"text":"With 1 comment","link":"https:\/\/herpescureadvocacy.com\/2024\/07\/24\/impressions-from-ihw-2024\/#comments"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2024\/07\/Screenshot-2024-07-24-075548.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2024\/07\/Screenshot-2024-07-24-075548.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2024\/07\/Screenshot-2024-07-24-075548.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2024\/07\/Screenshot-2024-07-24-075548.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2024\/07\/Screenshot-2024-07-24-075548.png?resize=1050%2C600&ssl=1 3x"},"classes":[]}],"_links":{"self":[{"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/posts\/389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/users\/205069572"}],"replies":[{"embeddable":true,"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/comments?post=389"}],"version-history":[{"count":6,"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/posts\/389\/revisions"}],"predecessor-version":[{"id":7206,"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/posts\/389\/revisions\/7206"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/media\/369"}],"wp:attachment":[{"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/media?parent=389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/categories?post=389"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/tags?post=389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}